Date | Title | Description |
05.12.2023 | Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines | Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful... |
31.10.2023 | MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies | MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to... |
30.10.2023 | Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program | Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry... |
26.10.2023 | MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013 | MaaT Pharma today announced that the DSMB unanimously recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host... |
26.10.2023 | Pharma announces positive outcome following DSMB review reinforcing confidence in phase 3 on-going trial. | Maat Pharma announces that the DSMB unanimoulsy recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host Disease... |
09.10.2023 | CorWave announces the grand opening of its manufacturing facility on the banks of the Seine, next to Paris | A French company that develops and manufactures innovative cardiac assist devices, held the grand opening of its new facility on the banks of the Seine in Clichy, next to... |
29.08.2023 | Citryll Announces Appointments of Eduardo Bravo as CEO and Tim Schenk as CBO | Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo... |
24.08.2023 | Alliance Promotion Microbiote applauds the new legislation securing stool collection in France | The Alliance Promotion Microbiote (APM), a prominent player dedicated to the development, production, and commercialization of therapeutic microbiome-based innovations,... |
30.06.2023 | Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer | Enterome today announces that the first patient was dosed in the Phase 1/2 'AUDREY' trial evaluating EO4010, the Company's third OncoMimics™ candidate, for the treatment of... |
14.06.2023 | Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma | Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry... |
31.05.2023 | Enterome announces sustained positive clinical outcomes with EO2401 | Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, today announces... |
23.05.2023 | Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis | Galecto, Inc., a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today... |
09.05.2023 | Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week | Exploratory analyses from the VE303 Phase 2 CONSORTIUM study identify statistically significant relationships between VE303 bacterial species and multiple parameters that... |
09.05.2023 | Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors | Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, announces the... |
25.04.2023 | Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies | Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has... |
25.04.2023 | Sinay, an Ocean Tech Company raises 5 M€ to help maritime corporations reconcile business efficiency with ocean biodiversity | Led by Seventure Partners’ Blue Forward Fund (France), in collaboration with Shift4Good (France and Singapore), Alpana Ventures (Switzerland), Normandie Littoral (France),... |
24.04.2023 | MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease | MaaT Pharma (EURONEXT), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival... |
20.04.2023 | Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients | Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates... |
12.04.2023 | Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma | Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD... |
04.04.2023 | Cerea Partners enters exclusive negotiations with Seventure Partners to acquire majority stake in Polaris | Cerea Partners, the investor-partner of the food & beverage universe companies, has entered into exclusive negotiations with a view to acquire a majority stake of Polaris... |
01.02.2023 | MD Anderson and Federation Bio Announce Collaboration to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers | Collaboration joins MD Anderson's expertise and capabilities with Fed Bio's proprietary ACT bacterial cell therapy platform to design and manufacture a complex, synthetic... |
12.01.2023 | Billennium integrates IDnow solution into its Inperly app | Billennium, a global IT solutions provider for businesses, has announced that it is partnering with IDnow, a leading identity proofing platform provider in Europe. Thanks to... |
05.01.2023 | ErVaccine closes a €4.5 million financing round and prepares to start clinical trial with its first therapeutic cancer vaccine in 2023 | ErVaccine Technologies, a biotech company and spin-off from the Centre Léon Bérard-Centre de Recherche en Cancérologie de Lyon, which develops next-generation therapeutic... |
05.01.2023 | Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study | Domain Therapeutics (“Domain” or “the Company”), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today... |
14.12.2022 | Ingenico and Izicap announce a strategic partnership | Ingenico and Izicap announce a strategic partnership to bring Izicap’s loyalty solutions to banks and acquirers using PPaaS, Ingenico’s Payments Platform as a Service. |
12.12.2022 | Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma | Enterome, a clinical stage company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform, today announces completion of... |
07.12.2022 | Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022 | Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform, today... |
16.11.2022 | Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022 | Enterome announces it will present updated efficacy, immunogenicity and safety data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in... |
16.11.2022 | SumUp reacts to cost of living with POS kit for small firms | SumUp is responding to the cost-of-living crisis by providing small and nano businesses with a new point-of-sale payments solution called POS Lite. |
11.11.2022 | SITC oral presentation yesterday by Dr Reardon / update on EO2401 ROSALIE study in rGBM | Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces... |
07.11.2022 | MaaT Pharma Announces Participation in Scientific and Investor Conferences in November | MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients... |
17.10.2022 | Clinical Microbiomics adds metabolomics to its portfolio with acquisition of MS-Omics to form the leading multi-omics provider for the microbiome field. | Clinical Microbiomics, a pioneering microbiome research
company, today announced its acquisition of MS-Omics, a leading metabolomics provider
based in Denmark. |
11.10.2022 | Clinical Microbiomics set to accelerate its expansion with EUR 10 million investment from Health for Life Capital™ II” managed by Seventure Partners | Seventure Partners, a worldwide leading microbiome venture capital, and Clinical Microbiomics A/S, a pioneering microbiome research company, today announced the completion of a... |
14.09.2022 | Foodtech startup STANDING OVATION closes a €12M Series A financing round to accelerate the development of its animal-free casein and cheese substitute production process | STANDING OVATION, a player in the food transition, announced today a Series A financing round of €12 million led by Astanor Ventures, with the participation of Peakbridge,... |
07.09.2022 | Top VC Funds In France To Finance Your Startup | According to PitchBook data, France is Europe's second-largest VC hub by the amount of capital invested. The ecosystem is growing and expanding year by year, as it shows, in... |
21.07.2022 | SumUp launches Magic Pay for the hospitality sector | SumUp, the financial partner for over 4 million small businesses worldwide, today announced the launch of SumUp Magic Pay, a QR code payment solution for the hospitality... |
20.07.2022 | Launchmetrics launches visual content platform and invests in AI | Launchmetrics' expansion into the visual content sector began in 2019 with the acquisition of Italian company IMAXtree. The deal underscored the company's interest in... |
20.07.2022 | Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases | Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel targeted live biotherapeutic products (LBPs) to prevent and treat diseases of high unmet... |
18.07.2022 | IDNow increases focus on offering for financial services sector in the UK | IDnow group, a leading European provider of identity proofing and digital identities, has appointed Mike Kiely as its Sales Director for Financial Services. Based in IDnow’s... |
11.07.2022 | String Bio, a biotech innovator, announced today that it has signed a strategic development agreement with Woodside Energy Technologies Pty Ltd, a wholly-owned subsidiary of global energy company Wood... | String Bio (String) and Woodside Energy are collaborating on potential production of sustainable protein ingredients from greenhouse gases.
Woodside Energy has invested... |
24.06.2022 | Intento Design secures the third round of investment to accelerate its commercial deployment | Intento Design, a Paris-based french company, developing and commercializing intelligent analog design automation tools to accelerate and secure chip production, announces... |
23.06.2022 | Galecto announces first patient enrolled in phase 2 trial of GB1211 in combination with Atezolizumab for first-line treatment of NSCLC | GB1211, Galecto's galectin-3 inhibitor, has shown potent anti-tumor effects and increased efficacy of checkpoint inhibition in pre-clinical models |
23.06.2022 | Below you can find a link with presentation published by the magazine DECIDEURS about Blue Forward Fund™ | Launched in December 2021 by Seventure Partners , Blue Forward Fund™ is the first European fund dedicated to blue economy... |
23.06.2022 | SumUp raises $624M at $8.5B valuation, with its payments and business tech now used by 4M SMBs | A decade ago, SumUp was one of the army of fintechs that made names for themselves with dongles that turned basic smartphones into card payment terminals. Today, the... |
06.06.2022 | Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, ... | Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces... |
06.06.2022 | Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022... | Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces... |
02.06.2022 | MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients | MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to... |
24.05.2022 | Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting | Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the details... |
24.05.2022 | Dermala, a consumer dermatology company, announces their second microbiome-powered line of topical and oral products for eczema-prone skin | DERMALA, the only personalized, clinically proven treatment for acne powered by the human microbiome, extends its product range to include a second microbiome-powered line of... |
03.05.2022 | Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies | Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec... |
21.04.2022 | INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial | MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to... |
13.04.2022 | BCD Bioscience, a Precision Prebiotic Fiber Company, Raises $12M In Series A Funding to Develop Lead Products | BCD Bioscience, a biotechnology company creating precision prebiotics from natural fibers, today announced that it has completed an oversubscribed Series A financing round of... |
29.03.2022 | Polaris raises €5 million to support its strong growth | Polaris, a pioneer in Omega 3 and leader in fatty acids with high concentrations of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), which play a key role in... |
28.03.2022 | MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease | A French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer,... |
11.03.2022 | Microbiome Space in Spotlight as Microbiotica Sets Funding Record | Competition is heating up in the microbiome niche as UK-based Microbiotica raised €60M (£50M) in a Series B round to advance two candidates designed to treat cancer and... |
11.03.2022 | Backing the Microbiome: The Investor Perspective | Life science research changes frequently, with new discoveries being published every day. Some of these discoveries form the basis of new biotech companies, but whether or not... |
07.03.2022 | Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics | Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series... |
22.02.2022 | Polaris and Golden Omega partner for the North American market | Polaris and Golden Omega are pleased to announce a new alliance which will allow Polaris to use Golden Omega’s extensive network in the North American Market for the... |
20.02.2022 | OIA launches project to produce alternative protein from dates | Focusing on its role in attracting foreign investments and advanced technologies to the sultanate, Oman Investment Authority (OIA) has signed an agreement with US-based... |
20.02.2022 | Oman Investment Authority, US firm join forces to advance food output | The Oman Investment Authority, or OIA, is collaborating with US-based food company MycoTechnology to set up innovative food production in the country.
The Vital Foods... |
14.02.2022 | Maat Pharma and Skyepharma have entered a partnership to establish the first exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France | MaaT Pharma (EURONEXT: MAAT), a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival... |
11.02.2022 | Seventure Partners expands focus to ‘blue’ economy BlueForwardFund™ announces first close, with the support of the Banque Populaire banks | Seventure Partners (Seventure), one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, under the leadership of Isabelle de... |
19.01.2022 | The start-up La Vie™ raises €25M and sets out to conquer the world with its new generation of plant-based meat | The first record raising of €25M in Series A financing from investment funds led by Seventure, and international celebrities that are committed to protecting the planet. This... |
13.01.2022 | Dermala Awarded Grand Prize in Inaugural Colgate Connect Challenge | DERMALA, a consumer dermatology company that develops novel treatments for chronic skin conditions, announces the brand's Grand Prize recognition in the global pitch... |
10.01.2022 | Three Startups Win First-Ever Colgate Connect Challenge | Colgate-Palmolive is pleased to announce the winners of the Colgate Connect Challenge, its first-ever global pitch competition aimed at startups from around the world focused... |
15.12.2021 | MDoloris Medical Systems & Mindray announce the CE Mark and launch of their Analgesia Nociception Index MR module in Europe. | MDoloris Medical Systems, leader in the field of objective analgesia/nociception monitoring during anesthesia and in intensive care, and Mindray, a global leader in developing... |
25.11.2021 | Prestashop acquired by MBE Worldwide | MBE and PrestaShop join forces to become a leading global commerce platform to power business growth. |
17.11.2021 | MDoloris Medical Systems announces the regulatory clearance and the upcoming launch of its Analgesia Nociception Index platform in Japan with Heiwa Bussan | MDoloris Medical Systems, a leader in the field of objective pain monitoring during anesthesia, announces today the regulatory clearance and marketing approval of its HFVI... |
03.11.2021 | MaaT Pharma announces successful Initial Public Offering on the regulated market of Euronext Paris | MaaT Pharma S.A. ("MaaT Pharma" or the “Company“), a French clinical-stage biotech and a pioneer in the development of microbiome2-based ecosystem therapies dedicated to... |
27.10.2021 | Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Dis... | Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and diseases, today announced that the... |
14.10.2021 | Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million | Additional EUR 32.5 million will support clinical readiness and accelerate lead immuno-virotherapy candidates toward clinical proof-of-concept. |
14.10.2021 | CattleEye Announce $2.5m Seed Investment | Belfast-based livestock monitoring technology company CattleEye announced today that it has closed a $2.5m seed investment round from a syndicate led by Techstart Ventures and... |
14.10.2021 | Digital Aquaculture Innovator Ecto Raises $7M in Series A Round from Rabobank and Aqua-Spark | Aquaculture data analytics disrupter Ecto has raised $7 million in financing led by the Rabo Food & Agri Innovation Fund and Aqua-Spark. New investor Seventure Partners also... |
13.10.2021 | Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders | Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25... |
13.10.2021 | BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005 | BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target... |
05.10.2021 | Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA | Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase... |
09.09.2021 | ViroVet and The Pirbright Institute are first to demonstrate efficacy of antivirals in ASFV – African Swine Fever Virus – infected pigs | Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine... |
02.09.2021 | A-Mansia Biotech’s pasteurised Akkermansia muciniphila is the firt next generation bacterium to get green light from EFSA’s cientific council | A crucial step has been taken by Belgian company A-Mansia Biotech, a co-spin-off of Wageningen University and UCLouvain. The European Food Safety Authority (EFSA) considers the... |
14.07.2021 | Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trials | Dopavision, a company pioneering the development of digital therapeutics, today announced the closing of a €12 million Series A financing round. Seventure Partners led the... |
12.07.2021 | Cegid acquires Talentsoft | Cegid, the specialist in business management solutions, plans to strengthen its position in the Payroll and Human Resources Management announces the acquisition of Talentsoft,... |
08.07.2021 | IDnow joins IDunion, the network initiative for digital identities funded by the Federal Ministry for Economic Affairs and Energy (BMWi) | IDnow, a leading European Platform-as-a-Service provider for identity verification, announces its participation in the IDunion network, which aims to build an open ecosystem... |
08.07.2021 | The partnership between Nexi and Izicap is strengthening: benefits for Italian Local Merchants | Nexi, the leading PayTech in Europe, announces the strengthening of its partnership with Izicap, a Fintech specialized in innovative CRM & Loyalty solutions dedicated to Local... |
30.06.2021 | CAPZA acquires a majority stake in Web Geo Services | CAPZA Growth Tech invests in Web Geo Services to make it a leading international player in Geolocation Intelligence. |
16.06.2021 | Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics | ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code the molecular interactions in the gut microbiome impacting... |
15.06.2021 | Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression | Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for... |
24.03.2021 | Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors | Phase1/2 clinical trials in patients with follicular lymphoma and marginal zone lymphoma expected to begin in Q2 2021
ENTEROME SA, a clinical stage biopharmaceutical... |
18.03.2021 | Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners explains Why investors need to think beyond ESG | Calls for genuine corporate responsibility efforts have been high on the agenda for some time, but the pandemic — and its wide-ranging impact on all organisations, including... |
17.03.2021 | MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease | MaaT Pharma announced today positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population... |
17.03.2021 | Viva Wallet, PrestaShop partner to allow localised payments for online merchants | Viva Wallet and PrestaShop have partnered to allow online merchants across Europe and the UK to accept fully localised payments in a few clicks, via the Viva Wallet... |
05.03.2021 | Hepster a german insurtech platform raises $10M Series A led by Element Ventures | Hepster, an insurtech platform from Germany, has raised $10 million in a Series A funding round led by Element Ventures. Also participating was Seventure Partners, MBMV and GPS... |
04.03.2021 | YSOPIA Bioscience Announces the First Positive Safety Results of its CAUSALITY Study in Obesity and Associated Metabolic Disorders, as well as the Inclusion of the Obese Patients in the Second Arm of ... | YSOPIA Bioscience, a French clinical stage biotechnology company specializing in the research and development of innovative drugs using the properties of key bacterial strains... |
03.03.2021 | IDnow Acquires identity Trust Management AG, a Leading Identity Verification Provider in Germany | IDnow, a leading provider of Identity Verification-as-a-Service solutions, today announced that it has agreed to acquire identity Trust Management AG, a leading international... |
02.03.2021 | BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin | BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that... |
25.02.2021 | Izicap awarded “Best Pos/payment solution 2021” MPE AWARDS | Izicap, the european card-linked CRM & loyalty platform leader, has been awarded "Best POS/Payment Solution" by the merchant payments ecosystem organisation within their... |
11.02.2021 | Launchmetrics and DBA Partner to Drive MIV for Influencers | Launchmetrics and Digital Brand Architects' campaign aims to drive Media Impact Value to influencers. |
09.02.2021 | Health for Life Capital II™ fund, managed by Seventure Partners, makes two new immuno-oncology (I/O) investments | Seventure led $10M round for new French company focusing on I/O-microbiome and provided $3M seed funding to ErVaccine, driving an increased I/O microbiome focus in fund... |
02.02.2021 | SumUp acquires Lithuanian mobile banking platform Paysolut | Global payments player SumUp has acquired the Lithuanian-born core banking system provider Paysolut, according to a press release shared exclusively with Tech.eu. |
27.01.2021 | Proteon Pharmaceuticals and Skretting to co-develop new phage-based solutions for aquaculture | Proteon Pharmaceuticals announced a strategic partnership with Skretting aimed at providing functional solutions to tackle health challenges in the aquaculture industry. The... |
26.01.2021 | The century of the microbiome: an exciting time for human health | While the pandemic might have caused some disruption, microbiome research hasn’t slowed down at all, notes Isabelle de Cremoux, CEO and Managing Partner, Seventure... |
26.01.2021 | Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners explains Why microbiota samples should be collected in all clinical trials? | In recent years, the understanding of how the microbiome and human health are linked has expanded considerably. We believe the rise in this understanding and the growing... |